Logo
x

Search category

Subscribe Now

Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

  • May 17, 2021
Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

  • May 17, 2021
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

  • September 22, 2020
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

  • September 22, 2020
Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

  • August 31, 2020
Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

  • August 31, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.